China approves Enhertu for second-line breast cancer treatment

24 February 2023

An antibody-drug conjugate (ADC) from AstraZeneca (LSE: AZN) and Daiichi Sankyo (TYO: 4568) has secured approval in China.

The nod for Enhertu (trastuzumab deruxtecan) comes around a month after the European Medicines Agency gave its blessing for the product, for people with HER2 low metastatic breast cancer.

Breast cancer is the most common cancer in Chinese women, with more than 415,000 diagnoses annually, and the first approval opens a path to creating a meaningful impact in an area of unmet medical need.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK